Fulgent Genetics, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
FLGT$26.15+10.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except par value data)
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| (unaudited) | ||
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $86,787 | $50,193 |
| Marketable securities | 205,952 | 285,884 |
| Trade accounts receivable, net of allowance for credit losses of $16,311 as of September 30, 2026, and $21,411 as of December 31, 2025 | 62,494 | 84,762 |
| Prepaid income taxes | 2,179 | 107,099 |
| Other current assets | 26,323 | 22,552 |
| Total current assets | 383,735 | 550,490 |
| Marketable securities, long-term | 359,550 | 369,269 |
| Fixed assets, net | 110,738 | 112,549 |
| In-process research & development | 68,490 | 68,490 |
| Other intangible assets, net | 78,310 | 64,791 |
| Goodwill | 53,861 | 25,080 |
| Other long-term assets | 24,245 | 22,856 |
| Total assets | $1,078,929 | $1,213,525 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $16,969 | $18,654 |
| Accrued liabilities | 22,077 | 34,057 |
| Customer deposit | 29,725 | 28,145 |
| Contract liabilities | 2,624 | 3,635 |
| Notes payable, current | 482 | 476 |
| Total current liabilities | 71,877 | 84,967 |
| Deferred tax liabilities | 6,957 | 6,936 |
| Unrecognized tax benefits | 5,816 | 7,283 |
| Other long-term liabilities | 9,571 | 7,624 |
| Total liabilities | 94,221 | 106,810 |
| Commitments and Contingencies (Note 8) | ||
| Stockholders’ equity | ||
| Common stock, $0.0001 par value per share, 50,000 shares authorized, 35,320 shares issued and 27,763 shares outstanding as of September 30, 2026, and 34,501 shares issued and 31,081 shares outstanding as of December 31, 2025 | 4 | 3 |
| Preferred stock, $0.0001 par value per share, 1,000 shares authorized, no shares issued or outstanding as of September 30, 2026, and December 31, 2025 | — | — |
| Additional paid-in capital | 531,564 | 574,520 |
| Accumulated other comprehensive (loss) income | (3,525) | 7,512 |
| Retained earnings | 462,446 | 529,954 |
| Total Fulgent stockholders’ equity | 990,489 | 1,111,989 |
| Noncontrolling interest | (5,781) | (5,274) |
| Total stockholders’ equity | 984,708 | 1,106,715 |
| Total liabilities and stockholders’ equity | $1,078,929 | $1,213,525 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.